Develops programmable molecular diagnostic kits that detect DNA and RNA pathogens with PCR-level accuracy using paper-based systems requiring no specialized equipment or training. These tests enable rapid, cost-effective, and decentralized identification of infections, including early Lyme disease detection at the tick bite, supporting timely intervention and reducing disease progression.
Funding
$1.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional molecular diagnostic tests for pathogens require specialized laboratory equipment and trained personnel, limiting accessibility and increasing the time to diagnosis, especially in point-of-care settings and resource-limited environments. This can lead to delays in treatment and potentially worsen patient outcomes.
Solution
En Carta Diagnostics develops programmable molecular diagnostic kits that enable rapid and accurate detection of DNA and RNA pathogens at the point of care. Their paper-based system eliminates the need for specialized equipment or extensive training, allowing individuals to perform tests in decentralized locations, including their own homes. The kits leverage synthetic biology technologies to achieve PCR-level accuracy in a simple, one-pot, one-step reaction. This approach facilitates early detection of infections, such as Lyme disease directly at the tick bite, enabling timely intervention and preventing disease progression.
Target Audience
The primary target audience includes individuals seeking rapid and accessible diagnostic solutions, healthcare providers in point-of-care settings, and researchers developing diagnostics for infectious diseases.
Features
- Paper-based molecular diagnostic kits for detecting DNA and RNA pathogens
- Proprietary technology enabling PCR-level accuracy without specialized equipment
- One-pot, one-step reaction for ease of use and rapid results
- Programmable design allows for adaptation to any DNA or RNA target
- Potential for room temperature stability, reducing storage and transportation costs
- Sustainable design minimizes carbon footprint and eliminates toxic waste